To evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mH8qNH
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
ACS Nano DOI: 10.1021/acsnano.7b04100 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h0ZFyU via...
-
Molecules, Vol. 24, Pages 2837: Bioavailability and Bioactivity of Encapsulated Phenolics and Carotenoids Isolated from Red Pepper Waste Mol...
-
Whether to wear a pollution filter Development of air quality forecasting system in Macedonia, based on WRF-Chem model Abstract Urban air qu...
-
Abstract Background Henoch–Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involve...
-
Denotation as Complex and Chronologically Extended: anvitābhidhāna in Śālikanātha's Vākyārthamātṛkā - I Abstract The two theories of ve...
-
UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. J Neurosurg. 2017 Apr 21;:1-9 Authors:...
-
Abstract Cerebral and systemic organ microvascular pathologies coexist with human Alzheimer’s disease (AD) neuropathology. In this study, w...
-
http://ift.tt/2s0PgaM
-
Tetracycline Repressors (TetRs) modulate multi-drug efflux pathways in several pathogenic bacteria. In Streptomyces, they additionally regul...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου